Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

NCT04909333 · Completed

Last updated 2026-05-28

This clinical trial tests whether an injection called exenatide can help diagnose hypoglycemia (low blood sugar) in people with a condition called endogenous hyperinsulinism.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 29 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-04 · est. completion 2024-04

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT04909333 ↗

Description as written by the study sponsor.

This study is to evaluate the concept of the exenatide test for diagnosis of EHH (earlier induction of symptomatic hypoglycemia compared to placebo within 4 hours after injection).

Treatments tested

Exenatide also known as Day 1 Exenatide; Day 2 : 0.9% saline solution Drug

Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed. Day2: The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously.
0.9% saline solution also known as Day 1 : 0.9% saline solution, Day 2 Exenatide Drug

Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed. Day2: The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.

Main thing measured	time to symptomatic hypoglycemia after exenatide test compared to placebo
Sponsor	University Hospital, Basel, Switzerland
Conditions studied	Endogenous Hyperinsulinism
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04909333 ↗